Name | Minodronic Acid |
Synonyms | Minodronic Acid MinodronicacidAPI Minodronic acid API MinodronicAcidhydrate MinodronateMonohydrate Minodronic Acid hydrate Minodronate Monohydrate MinodronicAcidMonohydrate Minodronic Acid Monohydrate P,P'-(1-Hydroxy-2-imidazo[1,2-a]pyridin-3-ylethylidene)bisphosphonicacidhydrate (1-Hydroxy-2-(iMidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonicacidhydrate P,P'-(1-Hydroxy-2-imidazo[1,2-a]pyridin-3-ylethylidene)bisphosphonic acid hydrate (1-Hydroxy-2-(iMidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid hydrate |
CAS | 155648-60-5 |
EINECS | 696-656-6 |
Molecular Formula | C9H14N2O8P2 |
Molar Mass | 340.163582 |
Water Solubility | Insoluble in water |
Appearance | powder to crystal |
Color | White to Light yellow to Light red |
Storage Condition | 2-8°C |
UN IDs | 2811 |
RTECS | SZ8562470 |
Hazard Class | 6.1 |
Packing Group | III |
pishiqing , Zhao Guoqing , Shen run , Chen Xinzhi
Abstract:
with imidazo [1,2-a] pyridine as raw material, through Mannich reaction, quaternization, cyano substitution, hydrolysis, the therapeutic drug for hypercalcemia, minodronate disodium, was prepared by reacting with phosphorous acid and then forming Salt. The total yield was 24%.
Key words:
minodronate disodium; Hypercalcemia; synthesis
DOI:
10.3969/j.issn.1001-8255.2004.04.001
cited:
year:
2004
Zhao Lijia , Wang Lihua , Hu Yaping , Xu Song , Chang-Qing Chen
Abstract:
1 Drug Profile trade name:(1)RECALBON Tablets1mg;(2)Bonoteo tabletables1 mg Common name: minodonic acid hydrate (minodonic acid) development code: Ono-5920,YH-529,YM-529 original research company: Japan Astellas Pharmaceutical Co., Ltd., Xiaoye Pharmaceutical Industry Co., Ltd.
Key words:
minodronic acid hydrate; Osteoporosis; carbon phosphate compounds
DOI:
10.7501/j.issn.0253-6376.[year].[issue].[sequence]
cited:
year:
2010
Abstract:
osteoporosis is a bone disease characterized by low bone mass and structural deterioration of bone tissue. The current clinical use of osteoporosis treatment drugs, such as estrogens, selective estrogen regulators, calcitonin and bisphosphonates are mainly beneficial to reduce bone resorption; There are some therapeutic drugs, such as fluoride and parathyroid hormone can increase bone formation. Anti-bone resorption therapy is very effective in the treatment of osteoporosis, even though it does not usually induce new bone formation.
Key words:
minodronic acid Nitrogenous bisphosphonates osteoporosis
DOI:
CNKI:SUN:YXJZ.0.2009-11-014
cited:
year:
2009